MOORESTOWN, N.J., March 24, 2020 (GLOBE NEWSWIRE) -- Tabula Rasa HealthCare®, Inc. (TRHC) (NASDAQ: TRHC), a healthcare technology company advancing the field of medication safety, is coordinating an effort to help Programs of All-Inclusive Care for the Elderly (PACE) with access to COVID-19 (SARS-CoV-2 RNA) testing kits. The testing kits are being made available through TRHC’s PACE pharmacy, CareKinesis®.
“We are committed to the wellness and safety of the participants we serve in PACE and of the many individuals who work directly with them,” said TRHC Chairman and CEO Calvin H. Knowlton, PhD. “Access to the COVID-19 test will help keep the nation’s most vulnerable risk group and their care team safe as possible during this COVID-19 pandemic.”
In addition to providing PACE partners with the COVID-19 (SARS-CoV-2 RNA) testing kits, TRHC’s CareKinesis pharmacy is also offering the BioIntelliSense BioSticker™ which will allow PACE centers to remotely monitor patients for COVID-19 symptoms, including fever, cough, and shortness of breath. The BioSticker is the first FDA-cleared, single-use device enabling 30 days of continuous vital sign monitoring.
“The ability to offer both the testing kit for diagnosis followed by the BioSticker to continue monitoring, is close to revolutionary,” said TRHC President Orsula V. Knowlton, PharmD. “Elderly patients are at high-risk for morbidity and mortality associated with COVID-19. Continuous monitoring of symptoms directly associated with COVID-19 may enable early detection and interventions that prevent exacerbation and hospitalization of this high-risk population.”
PACE is a federal program providing comprehensive medical and social services to individuals 55 and older who are nursing-home eligible. The goal of PACE is to keep participants living in their own communities and to provide quality medical care. Currently, 131 PACE programs operate 263 PACE centers in 31 states, serving over 53,899 participants.
About Tabula Rasa HealthCare®
Tabula Rasa HealthCare (TRHC) is a leader in patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize performance to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. Medication risk management is TRHC’s lead offering, and its cloud-based software applications provide solutions for a range of payers, providers and other healthcare organizations. For more information please visit www.trhc.com.
About CareKinesis®
CareKinesis partners with healthcare organizations to provide personalized medication therapy management and pharmacy services for high-risk populations. The results are enhanced medication-related outcomes and greater operational efficiency. CareKinesis delivers individually customized medicine using unique robotic technology and a proprietary web-based electronic medication management and reporting platform, EireneRx®. It is the first, national PACE-specific pharmacy and the market leader. For more information, please visit www.carekinesis.com.
Forward-Looking Statements
This press release includes forward-looking statements that we believe to be reasonable as of today’s date, including statements regarding Medication Risk Mitigation technology. Such statements are identified by use of the words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “projects,” “should,” and similar expressions. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: the need to innovate and provide useful products and services; risks related to changing healthcare and other applicable regulations; increasing consolidation in the healthcare industry; managing our growth effectively; our ability to adequately protect our intellectual property; and the other risk factors set forth from time to time in our filings with the SEC, including those factors discussed under the caption “Risk Factors” in our most recent annual report on Form 10-K, filed with the SEC on March 1, 2019, and in subsequent reports filed with or furnished to the SEC, copies of which are available free of charge within the Investor Relations section of the TRHC website ir.trhc.com or upon request from our Investor Relations Department. Any forward-looking statement speaks only as of the date on which it was made. TRHC assumes no obligation and does not intend to update these forward-looking statements, except as required by law, to reflect events or circumstances occurring after today’s date.
Contact
Media Relations
Amanda Bednar
abednar@TRHC.com
T:856-912-57147
Dianne Semingson
dsemingson@TRHC.com
T: 215-870-0829
Investors
Frank Sparacino
fsparacino@trhc.com
Office 866.648.2767